Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Ataxia Law can help you by evaluating your case
A 2022 systematic review found mixed outcomes: some gastroparesis patients tolerated low-dose GLP-1 therapy without symptom exacerbation, while others experienced significant worsening
Get personalized peptide recommendations from our physician team
or Vision changes
27) Astellas Pharma 2022 Revenue: Astellas Pharmas annual revenue for the year ended March 31, 2023, was $1.52 trillion JPY ($11.55 billion USD), a 17.16 percent increase from $1.30 trillion JPY ($11.80 billion USD) for the year ended March 31, 2022
US$ 22.67
,aspect=ignore)
US$ 21.52
US$ 23.82
US$ 23.38
US$ 25.86
,aspect=ignore)
US$ 20.99
